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Background
For many cancers, and malignant melanoma (MM)
makes no exception, regional lymph node (RLN) status is
decisive for subsequent patients’ outcome. But particu-
larly for MM, stage III comprises a very heterogeneous
group of patients, from those with microscopic invasion
diagnosed by sentinel node (SN) biopsy to those with
matted nodes. Correct staging of patients with clinically
free RLN requires SN biopsy. Because this is an invasive
maneuver, various substitutes were searched. Thus, in lit-
erature there are conflicting references to a possible link
between Melanoma Inhibitory Activity (MIA) serum con-
centration and SN status [1,2]. MIA, a protein secreted
by malignant melanocytes into the extracellular space,
blocks the melanoma cells attachment to fibronectin and
laminin. Thus MIA increases malignant cells mobility
and promotes local invasion and metastasis [3]. In this
context, we sought a connection between RLN status and
MIA serum concentration in our group of patients.
Materials and methods
150 patients with non-metastatic cutaneous MM were
treated in our clinic between 2009 and 2013. They were
staged according to 2009 AJCC (American Joint Cancer
Committee) staging system. 47 patients were assigned to
stage III: 37 presented with clinically evident lymphadeno-
pathies and 10 had positive SN. SN biopsy was performed
in 61 patients with intermediate thickness MM and no
clinical or ultrasound signs of RLN metastasis. MIA was
measured preoperatively in all patients. A cut-off value of
9.4 ng/mL was calculated using ROC curve [4]. Patients
were divided in four groups according to RLN status
(N0/N1/N2/N3).
Results
Mean and median MIA serum concentration progres-
sively increased along with the number of metastatic
RLN. The difference between mean and median MIA
values in the 4 groups was not accidental, but the con-
sequence of different tumor load (p = 0.001). Only
N0 patients had mean and median MIA concentrations
less than 9.4 ng/mL, for all the other N categories,
values surpassing the threshold. SN identification rate
was 100%. The mean and median MIA serum value in
SN positive group were higher than in SN negative one,
but the differences were not statistically significant
(p=0.6191) and in both cases didn`t exceed the upper
normal limit.
Conclusion
MIA serum concentration increases with RLN tumor
burden. In our study SN status didn’t correlate with MIA
value, but the small number of patients prevents us to
draw a conclusion.
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